Introduction
An adequately performed animal experiment is still necessary to distinguish carcinogenic from noncarcinogenic chemicals. The recognition of carcinogens is straightforward if tumors arise in high yields and in tissues not forming tumors spontaneously in the species under test. A borderline activity is much more difficult to interpret, and species, strain and tissue-specific effects impede easy extrapolation to the human situation. A better understanding of the underlying mechanisms is therefore demanded.
Since the pioneering work of the Millers and their associates (1) , it is widely accepted that aromatic amines have to be metabolically activated and that the reaction of metabolites with DNA produces a decisive lesion which initiates the process of tumor formation. Accordingly the biological effect and to explain species, strain and tissue susceptibility by differences in exposure of the responsive tissue to reactive metabolites, due to specific balances between activating and inactivating metabolism. This concept had to be extended when the modulating properties of repair processes were detected. However, even if persistence of the DNA lesion is included in the considerations, it is difficult to find satisfactory correlations. From our studies with aminostilbene derivatives, which are carcinogenic and produce tumors quite selectively in sebaceous glands of rats, we conclude that substance-related effects not involving metabolic activation as well as tissue specific parameters contribute and may ultimately determine the biological effect (2, 3) . Tissue-specific proliferation rates and their modulation and factors which influence processes collectively called promotion, including hormonal control, are such secondary parameters. These aspects have been widely neglected in cell-free and cell culture system investigations of the mechanism of metabolic activation. Recent results from studies of the fate of aminostilbene derivatives in rats will therefore be described to illustrate some of the problems involved in whole animal experiments and to support the proposed role of secondary factors in tumor formation.
Tissue Exposure and Primary Lesion
It is difficult to follow the concentration of individual metabolites in specific tissues with time in the intact animal. Usually metabolites are isolated and identified in urine, bile or sometimes blood, but reactive intermediates are not readily obtained from these sources. In tissues, the final reaction products with cellular macromolecules are therefore considered to indicate their presence. Covalent binding to proteins may be used to approximate tissue exposure. Although protein adducts may not reflect the exact pattern of metabolites reacting with nucleic acids, they may be formed by common metabolic precursors or even the same ultimate reactive metabolites. We have tentatively identified one of the protein adducts as a sulfinic acid amide which results from the reaction of trans4-nitrosostilbene with the SH-group of cysteine (4). The adduct can be analyzed by mild acidic hydrolysis which releases trans4-aminostilbene (Fig. 1 ). It constitutes 70% of the adducts in hemoglobin and it is also present in plasma and tissue proteins to a smaller extent (5) . This indicates the presence not only of trans4-nitrosostilbene but also of trans-4-Nhydroxylaminostilbene in blood and tissue. Both compounds are direct mutagens and therefore have genotoxic potential. Methylmercapto derivatives of trans4-acetylaminostilbene (trans-AAS) have also been identified after acidic hydrolysis of tissue proteins (5) , which indicates the reaction of methionine with a hydroxamic acid ester, which is also potentially genotoxic.
Three days after administration of radiolabeled trans-AAS to rats, protein-bound metabolites are found in all tissues, and protein binding roughly parallels total radioactivity in a given tissue at that time (Table 1 ). This allows approximation of tissue exposure even in tissues from which macromolecules have not been isolated. According to these criteria, all tissues measured are exposed to reactive Tissue-specific effects are often thought to be caused by tissue-specific metabolic activation. Total binding to proteins and nucleic acids does not account for the possible presence of particularly critical metabolites. Therefore, the metabolic pathways, distribution and sites of formation for reactive metabolites must be determined. Studying the metabolism of acute toxic doses of trans-AAS, we have now obtained additional data which support our conclusion that liver metabolism largely determines exposure of extrahepatic tissues (6) . Acute toxic doses of trans-AAS quite specifically damage the proliferating isthmus cells in the antrum of the glandular stomach and the blood cell-forming bone marrow (7) . Since these effects can be suppressed by pretreatment with methylcholanthrene (MC), but not with phenobarbital (PB), this indicates a role of metabolic activation ( Table 2 ). The consequences of MC pretreatment were therefore studied on the level of metabolism, tissue exposure and DNA binding. Phase I and phase II metabolism are altered considerably (Tables 3 and 4 ). The conjugation pattern in urine and bile indicates that the conjugation capacity is increased by the protecting pretreatment. Binding to blood proteins, particularly hemoglobin, is lowered, which indicates that less N-oxidized, i.e., activated, metabolites are distributed by the blood stream ( Table 5) . As a consequence, all extrahepatic tissues are less exposed (Table 6 ). In the toxic situation, the glandular stomach as a target tissue is exposed to the same extent as other extrahepatic tissues, and the protective pretreatment lowers exposure and DNA damage in all tissues. It is therefore unlikely that metabolic activation specific to this tissue causes toxicity and that tissue-specific inactivation provides protection. This is in accordance with previous experiments with nontoxic doses, in which a similar pattern of DNA adducts revealed that all four of the above studied tissues are exposed to the same reactive metabolites (10) . However, this may not hold true if the carcinogen is administered chronically, because drug-metabolizing enzymes in liver or extrahepatic tissues may be induced. However, this confounding effect can be excluded be- (Table 7) .
Repair
Although accumulation of DNA damage in the previous experiment already precluded tissuespecific repair of the initial lesions as a gross modulating factor, we measured the elimination rate of DNA-bound metabolites at different times during the course of administration and found it to remain constant up to the 12th dose (Table 7) . Repair processes are therefore neither induced nor inhibited with this protocol. (9); (x, n = 2).
Initiation-Promotion
At this point, the question had to be answered whether or not the persistent and accumulating DNA damage could be regarded at all as indicating an initial lesion in terms of tumor initiation. The possibility had to be ruled out that the total binding measured with DNA obtained from whole tissue homogenates is entirely irrelevant with respect to tumor formation. Actually one should expect only that some, as yet undefined, critical lesion, which constitutes only a small fraction of total binding, would correlate with biological effects. However, pharmacokinetic considerations make it quite likely that a certain correlation also exists between a critical lesion and the total DNA lesion. As long as the critical event cannot be defined, this correlation cannot be determined. It should be possible, however, to demonstrate whether or not there is a critical lesion at all among the persistent DNA-lesions, if secondary effects can be found which amplify the primary effect. For liver, partial hepatectomy is known to increase cell proliferation and therefore to improve fixation of an initial lesion (11, 12) . In addition, promoters like PB and DDT may enhance the growth of intiated cells (13) (14) (15) . We have therefore mg/kg). After 24 hr, proteins and DNA were isolated from different tissues (10); (x, n = 2, deviation <17%). (x, n = 3, standard deviation <25%); (2) to determine the elimination rate during the administration period, only one labeled dose was administered after various unlabeled trans-AAS doses, and DNA binding was measured 3 and 17 days after the last dose (x, n = 2).
performed an initiation-promotion experiment and included diethylstilbestrol (DES) to test the promoting properties of estrogenic hormones in liver (16, 17) . The protocol is shown in Figure 2 and the results are shown in Table 8 .
The trans-AAS dose turned out to be moderately carcinogenic, producing sebaceous gland tumors in half the animals within one year. Up to this time, neither enzyme-deficient foci nor hyperplastic nodules could be detected in the liver. If trans-AAS administration was followed by partial hepatectomy, preneoplastic lesions as well as hepatomas were observed. Feeding DDT and DES alone to pretreated animals produced similar effects. Tumor formation was particularly increased and the latent period shortened if partial hepatectomy and promoter feeding were combined.
These results clearly demonstrate that trans-AAS induces critical lesions in liver. In addition, tumors grew in mammary tissue, a tissue which had been shown to be exposed the least (Table 1) . DES aThe experiment was terminated after 54 weeks, except for the control groups. Tumors were histologically verified. Hyperplastic nodules are contained in the incidence rate. It was not attempted to specify the malignancy of liver tumors. (Table 10) . It is therefore unlikely that promoters contribute to fixation of DNA damage to an extent comparable to that of partial hepatectomy. These findings would support the notion that a specific lesion is amplified by partial hepatectomy directly, i.e., through DNA synthesis, and by promoters indirectly through stimulating the expression of altered cell properties. An irreversible change would be a prerequisite for both mechanisms.
The last two experiments demonstrate, in addition, that the applied procedures do not only affect the liver. A preceding partial hepatectomy increases DNA binding in all extrahepatic tissues (Table 9 , in this situation extrahepatic metabolism contributes significantly), and decreases the elimination between day 3 and 17 (data not shown) of DNAbound metabolites in glandular stomach and lung. The latter effect is also observed with subsequent partial hepatectomy and is more pronounced in lung than in glandular stomach and kidney. After 2 weeks of promoter feeding, specific DNA binding is greater in experimental than in control animals in all tissues studied. In kidney, even an absolute in- crease is observed; this is largest with DES (Table  10) .
Conclusions
According to the definition outlined in the introduction, trans-AAS is a strong and complete carcinogen. This statement may now be modified: trans-AAS is a complete carcinogen for sebaceous glands, but an incomplete carcinogen for liver and mammary tissue, and it may be an incomplete carcinogen for other tissues as well. Since the extent of accumulating and persistent DNA damage, which apparently indicates the presence of initiating DNA lesions, does not correlate with the biological effects, it has to be postulated that secondary effects modulate the primary lesion and may ultimately determine where the process of tumor formation starts and how fast it develops. The proliferation rate and endogenous hormonal stimulation may be decisive in Zymbal's gland. In mammary tissue, an exogenous hormonal stimulus (or inhibition of prolactin inhibiting factor) was most effective. This raises the question, what does trans-AAS lack to make it a complete carcinogen for liver? Obviously, the promoting properties, rather than the initiating, are absent. 2-Fluorenylacetamide has been shown to possess both properties. It induces drug metabolizing enzymes (18) (19) (20) and thus shares a trait common to other typical promoters, and it is also toxic to liver tissue. Trans-AAS, in contrast, neither induces enzymes (21) nor is toxic to liver, even in lethal doses (7) .
Other examples of incomplete liver carcinogens have been described recently. 2-Methyl-4-dimethylaminoazobenzene (22, 23) was classified noncarcinogenic but induced tumors after additional promotion. Benzo(a)pyrene (24) is a complete carcinogen for many tissues after local administration, but produces liver tumors only with partial hepatectomy and promotion. N-Acetylaminobiphenyl (25), a known carcinogen for mammary tissue in rats, has also been shown to initiate liver cells. It will therefore be necessary to include the multistage characteristics of carcinogenesis (26) in risk evaluations and to consider both genotoxic and epigenetic properties to assess the carcinogenic potential more precisely. The results described indicate that epigenetic effects may be unrelated to reactive metabolites, since trans-AAS metabolites react with DNA and proteins to the same extent as hepatotoxic and hepatocarcinogenic aromatic amines.
